These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15330798)

  • 21. Saving lives with accurate HER2 testing.
    Ross JS
    Am J Clin Pathol; 2010 Aug; 134(2):183-4. PubMed ID: 20660318
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
    J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2 testing in the UK: further update to recommendations.
    Walker RA; Bartlett JM; Dowsett M; Ellis IO; Hanby AM; Jasani B; Miller K; Pinder SE
    J Clin Pathol; 2008 Jul; 61(7):818-24. PubMed ID: 18381380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice.
    Shaaban AM; Purdie CA; Bartlett JM; Stein RC; Lane S; Francis A; Thompson AM; Pinder SE;
    J Clin Pathol; 2014 Feb; 67(2):161-7. PubMed ID: 24062360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections?
    Sumiyoshi K; Shibayama Y; Akashi S; Nohara T; Iwamoto M; Kobayashi T; Nishimura H; Yoshinaka R; Harada T; Tanigawa N
    Oncol Rep; 2006 Apr; 15(4):803-8. PubMed ID: 16525662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer.
    Di Palma S; Collins N; Bilous M; Sapino A; Mottolese M; Kapranos N; Schmitt F; Isola J
    J Clin Pathol; 2008 Jun; 61(6):757-60. PubMed ID: 18326010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current technologies for HER2 testing in breast cancer.
    Moelans CB; de Weger RA; Van der Wall E; van Diest PJ
    Crit Rev Oncol Hematol; 2011 Dec; 80(3):380-92. PubMed ID: 21273092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The importance of accuracy in HER2 testing.
    Gonzalez-Angulo AM
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):529-31. PubMed ID: 23073051
    [No Abstract]   [Full Text] [Related]  

  • 29. HER2 Immunohistochemistry-Guided Targeted Fluorescence In Situ Hybridization Analysis Does Not Help Identify Intratumoral Heterogeneity in Breast Cancer.
    Gulbahce HE; Factor R; Geiersbach K; Downs-Kelly E
    Arch Pathol Lab Med; 2016 Aug; 140(8):741. PubMed ID: 27472230
    [No Abstract]   [Full Text] [Related]  

  • 30. Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy.
    Ballinger TJ; Sanders ME; Abramson VG
    Clin Breast Cancer; 2015 Jun; 15(3):171-80. PubMed ID: 25516402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status of HER2 testing: caught between a rock and a hard place.
    Schnitt SJ; Jacobs TW
    Am J Clin Pathol; 2001 Dec; 116(6):806-10. PubMed ID: 11764067
    [No Abstract]   [Full Text] [Related]  

  • 32. HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations.
    Starczynski J; Atkey N; Connelly Y; O'Grady T; Campbell FM; di Palma S; Wencyk P; Jasani B; Gandy M; Bartlett JM;
    Am J Clin Pathol; 2012 Apr; 137(4):595-605. PubMed ID: 22431536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Guideline of HER2 detection in breast cancer].
    Group of guideline of HER2 detection in breast cancer
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):631-3. PubMed ID: 17134576
    [No Abstract]   [Full Text] [Related]  

  • 34. FISH gene test set to become standard-of-care in breast cancer diagnosis.
    Expert Rev Mol Diagn; 2003 Jul; 3(4):405-6. PubMed ID: 12877379
    [No Abstract]   [Full Text] [Related]  

  • 35. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis.
    Dendukuri N; Khetani K; McIsaac M; Brophy J
    CMAJ; 2007 May; 176(10):1429-34. PubMed ID: 17485695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme.
    Bartlett JM; Ibrahim M; Jasani B; Morgan JM; Ellis I; Kay E; Magee H; Barnett S; Miller K
    J Clin Pathol; 2007 Jul; 60(7):816-9. PubMed ID: 16963466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Importance of accurate HER2 testing in patients with metastatic breast cancer.
    Gonzalez-Angulo AM
    Clin Adv Hematol Oncol; 2010 Dec; 8(12):873-4. PubMed ID: 21326164
    [No Abstract]   [Full Text] [Related]  

  • 38. The knowns and the unknowns in HER2 testing in breast cancer.
    Gown AM; Goldstein LC
    Am J Clin Pathol; 2011 Jul; 136(1):5-6. PubMed ID: 21685025
    [No Abstract]   [Full Text] [Related]  

  • 39. Automated HER2 testing: personalized healthcare for breast cancer patients enabled by novel molecular morphology methods.
    Nitta H
    MLO Med Lab Obs; 2013 Jun; 45(6):18-20. PubMed ID: 23875439
    [No Abstract]   [Full Text] [Related]  

  • 40. [Molecular diagnosis of breast cancer].
    Tsuda H
    Nihon Geka Gakkai Zasshi; 2002 Jun; 103(6):487-91. PubMed ID: 12094701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.